Jeil Pharma Holdings Inc (KRX: 002620)

Market Cap	126.49B
Revenue (ttm)	783.56B
Net Income (ttm)	-39.54B
Shares Out	15.35M
EPS (ttm)	-2,575.85
PE Ratio	n/a
Forward PE	n/a
Dividend	50.00 (0.61%)
Ex-Dividend Date	n/a

Volume	3,706
Open	8,300.00
Previous Close	8,350.00
Day's Range	8,170.00 - 8,650.00
52-Week Range	7,430.00 - 14,360.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Jeil Pharma Holdings

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 39
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 002620

Financial Performance

In 2023, Jeil Pharma Holdings's revenue was 804.04 billion, an increase of 1.40% compared to the previous year's 792.96 billion. Losses were -16.25 billion, -78.20% less than in 2022.